CYTO - Altamira Therapeutics Ltd. Quarterly EPS earnings growth

Altamira Therapeutics (CYTO) - corporate logo

Altamira Therapeutics (CYTO) is attracting experts in drug delivery to brain and ear tissues by offering opportunities within an innovative niche. The quarterly EPS growth rate demonstrates profit dynamics, where 0.00 represents the current level of the metric. This correlates with a narrow market moat and slow product rollout, as well as critical capital burn risks and past research failures.

altamiratherapeutics.com (CYTO) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 01/04/2025

Financial and market metric breakdowns for Altamira Therapeutics (CYTO)

- share price and expert price forecast:
Stock Price altamiratherapeutics.com|CYTO - Fair Value Consensus
- market capitalization statistics:
Market Capitalization Auris Medical|CYTO - Total Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share Altamira Therapeutics|CYTO - Accounting Value of Company|Market Capitalization to Book Value Ratio altamiratherapeutics.com|CYTO - Company Total Assets
- company liabilities and liquidity data:
Debt to Equity Altamira Therapeutics|CYTO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio altamiratherapeutics.com|CYTO - Company Cumulative Indebtedness|Debts to Book Capitalization Auris Medical|CYTO - Company Long-Term Debts|Company Short-Term Debt Altamira Therapeutics|Quick Ratio altamiratherapeutics.com
- earnings and market multiples details:
CYTO - Net Financial Result|Expected Profit Altamira Therapeutics|CYTO - Company Value to Net Income|Forward P/E Multiple altamiratherapeutics.com|CYTO - PEG Multiple|Enterprise Value to EBITDA Ratio Auris Medical|CYTO - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Altamira Therapeutics|CYTO - Earnings per share for the last four quarters|Quarterly EPS earnings growth altamiratherapeutics.com|CYTO - Earnings per share increase in current year|Earnings growth forecast for next year Altamira Therapeutics
- sales revenue and business income indicators:
CYTO - Company Total Revenue|Company Projected Revenue altamiratherapeutics.com|CYTO - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Auris Medical
Fundamental company valuation:Altamira Therapeutics Ltd - CYTO
Manufactured product of Altamira Therapeutics Ltd.

This metric measures the year-over-year quarterly dynamics of net earnings per share, allowing for an assessment of capital management efficiency and business profitability. By analyzing the quarterly EPS growth rate, an investor can gauge the speed of profit generation, which is critical for Altamira Therapeutics (CYTO) given the absence of commercial products and the risks of development cessation due to liquidity shortages.

Competitor analysis

HLN: Quarterly EPS earnings growth|Kenvue Inc - Year-over-year earnings per one share growth for the last 12 months|VRNA (Verona Pharma Corp) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Jyong Bio MENS|Year-over-year earnings per share growth for the last twelve months Ligand Pharmaceuticals (LGND)|AMRX (amneal.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth PRGO (Perrigo)|Quarterly EPS earnings growth Alvotech S.A. ALVO|LQDA - Year-over-year earnings per share growth for the last twelve months|GLPG: Year-over-year earnings per share growth for the last twelve months|ANIP (ANI Pharmaceuticals) - Year-over-year net earnings per share growth for the last 12 months|MNKD: Year-over-year earnings per share growth rate for the last twelve months|AMPH (Amphastar Pharmaceuticals, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Pacira Pharmaceuticals|Year-over-year earnings per share growth for the last twelve months ARS Pharma (SPRY)|Year-over-year net earnings per share growth for the last 12 months Theravance Corp TBPH|Quarterly EPS earnings growth AQST (Aquestive Therapeutics)|Year-over-year net earnings per share change for the last twelve months scPharmaceuticals, Inc. (SCPH)|TECX - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months TNXP (Tonix Pharma)|SXTC: Quarterly EPS earnings growth|Eupraxia Pharmaceuticals Inc. (EPRX) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months BHST|EXOZ: Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months ORMP (Oramed Pharmaceuticals)|Year-over-year earnings per share growth rate for the last twelve months ENTX|Quarterly EPS earnings growth HYFT (MindWalk)|Year-over-year earnings per one share growth for the last 12 months ABVC|Cumberland Pharmaceuticals - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months quantumbiopharma.com|FibroGen (FGEN) - Year-over-year earnings per share growth for the last twelve months|Telomir Pharmaceuticals Inc - Year-over-year earnings per one share growth for the last 12 months|RANI (Rani Therapeutics Holdings) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Synergy CHC Corporation|Year-over-year earnings per share growth for the last twelve months Rallybio Corporation (RLYB)|LEXX: Year-over-year net earnings per share trend for the last twelve months|Quarterly EPS earnings growth PULM (Pulmatrix)|Pheton Holdings Limited (PTHL) - Earnings per share growth in annualized terms for the last twelve months|APM: Year-over-year net earnings per share growth for the last 12 months|LYRA - Quarterly EPS earnings growth|IBO (Impact BioMedical) - Year-over-year net earnings per share growth for the last 12 months|TNFA: Year-over-year earnings per share growth rate for the last twelve months|YCBD (cbdMD Inc.) - Quarterly EPS earnings growth|PainReform Ltd (PRFX) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth LIPO|Year-over-year net earnings per share growth for the last 12 months OptiNose Corp OPTN|Year-over-year earnings per share growth for the last twelve months Pieris Pharmaceuticals PIRS|Year-over-year net earnings per share change for the last twelve months procapsgroup.com (PROC)|Petros Pharmaceuticals, Inc. - Quarterly EPS earnings growth|Qilian International Holding Group (QLI) - Year-over-year net earnings per share growth for the last 12 months|SLRN (ACELYRIN, Inc.) - Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months TFF Pharmaceuticals, Inc (TFFP)